

## บรรณานุกรม

- วิทยาศาสตร์การแพทย์, กรม. 1999. นโยบายกระทรวงสาธารณสุข, Top 10 organisms isolated from blood 1999, Top 10 organisms isolated from CSF. (Computer Data). URL: <http://www.dmsc.moph.go.th/webroot/ars/index.htm> : ศูนย์เฝ้าระวังเชื้อดื้อยาแห่งชาติ
- สำนักงานปลัดกระทรวงสาธารณสุข. กองโรงพยาบาลภูมิภาค. 2542. แนวทางการตรวจทางห้องปฏิบัติการ. กรุงเทพฯ.
- Amari, E.B., et al. 2001. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of *Pseudomonas aeruginosa* bacteremic isolates, Clin Infect Dis. 33 : 1859-1864.
- American Thoracic Society. 1995. Hospital-acquired pneumonia in adults : diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies, Am J Respir Crit Care Med. 153 : 1711-1725.
- Archibald, L., et al. 1997. Antimicrobial resistance in isolates from inpatients and outpatients in the United States : increasing importance of the intensive care unit, Clin Infect Dis. 24 : 211-215.
- Arruda, E.A.G., et al. 1999. Nosocomial infections caused by multiresistant *Pseudomonas aeruginosa*, Infect Control Hosp Epidemiol. 20 : 620-623.
- Atlas, R.M. 1995. Principles of Microbiology. USA : McGraw-Hill.
- Bonaventura, G.D., et al. 1998. Evaluation of the E test for antimicrobial susceptibility testing of *Pseudomonas aeruginosa* isolates from patients with long-term bladder catheterization, J Clin Microbiol. 36 : 824-826.
- Bonfinglio, G. 1998. Mechanism of beta-lactam resistance amongst *Pseudomonas aeruginosa* isolated in an Italian survey, J Antimicrob Chemother. 42 : 697-702.
- Bonfinglio, G., et al. 1998. Antibiotic resistance in *Pseudomonas aeruginosa* : an Italian survey, J Antimicrob Chemother. 41 : 307-310.

- Bouza, E., et al. 1999. *Pseudomonas aeruginosa* : a survey of resistance in 136 hospitals in Spain, *Antimicrob Agents Chemother.* 43 : 981-982.
- Brewer, S.C., et al. 1996. Ventilator-associated pneumonia due to *Pseudomonas aeruginosa*, *Chest.* 109 : 1019-1029.
- Brooklyn Antibiotic Resistance Task Force. 2002. The cost of antibiotic resistance : effect of resistance among *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa* on length of hospital stay, *Infect Control Hosp Epidemiol.* 23 : 106-108.
- Brown, D.F.J. and Brown L. 1991. Evaluation of the E test, a novel method of quantifying antimicrobial activity, *J Antimicrob Chemother.* 27 : 185-190.
- Bush K. 2001. New  $\beta$ -lactamases in gram-negative bacteria : diversity and impact on the selection of antimicrobial therapy, *Clin Infect Dis.* 32 : 1085-1089.
- Carmeli, Y. 1999. Emergence of antibiotic-resistant *Pseudomonas aeruginosa* : comparison of risks associated with different antipseudomonal agents, *Antimicrob Agents Chemother.* 43 : 1379-1382.
- Carmeli, Y., et al. 1999. Health and economic outcomes of antibiotic resistance in *Pseudomonas aeruginosa*, *Arch Intern Med.* 159 : 1127-1132.
- Conway, S.P., et al. 2000. Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbation in adults with cystic fibrosis, *Ann Pharmacother.* 34 : 1238-1242.
- Edwards, J.R. 1995. Meropenem : a microbiological overview, *J Antimicrob Chemother.* 36 : 1-17.
- Forbes, B.A., Sahm, D.F. and Weissfeld, A.S. 1998. *Diagnostic microbiology.* USA : Mosby.
- Gales, A.C., et al. 2001. Characterization of *Pseudomonas aeruginosa* isolates : Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999, *Clin Infect Dis.* 32 (Suppl 2) : S146-S155.

- Garner, J.S., et al. 1998. CDC definitions for nosocomial infections, *American J Infect Control*. 16 : 128-140.
- Gaynes, R.P. and Culver, D.H. 1992. Resistance to imipenem among selected gram-negative bacilli in the United States, *Infect Control Hosp Epidemiol*. 13 : 10-14.
- Giamarellou, H. 2001. Antipseudomonal antibiotics, *Med Clin North Am*. 85 : 19-42.
- Hamer, D.H., 2000. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant *Pseudomonas aeruginosa* with aerosolized colistin, *Am J Respir Crit Care Med*. 162 : 328-330.
- Henwood, C.J., et al. 2001. Antimicrobial susceptibility of *Pseudomonas aeruginosa* : results of a survey and evaluation of the British Society for antimicrobial chemotherapy disc susceptibility test, *J Antimicrob Chemother*. 47 : 789-799.
- Hirakata, Y., et al. 2003. Clinical and Bacteriological Characteristics of IMP-Type Metallo- $\beta$ -Lactamase-Producing *Pseudomonas aeruginosa*, *Clin Infect Dis*. 37 : 26-32.
- Iaconis, J.P, et al. 1997. Comparison of antibacterial activities of meropenem and six other antimicrobials against *Pseudomonas aeruginosa* isolates from North American studies and clinical trials, *Clin Infect Dis*. 24(Suppl 2) : S191-196.
- Kessler, R.E. 2001. Cefepime microbiologic profile and update, *Pediatr Infect Dis J*. 20 : 331-336.
- King, A., Shannon, K. and Phillips, I. 1995. Resistance to imipenem in *Pseudomonas aeruginosa*, *J Antimicrob Chemother*. 36 : 1037-1041.
- Kohler, T., et al. 1999. Carbapenem activities against *Pseudomonas aeruginosa* : respective contributions of OprD and efflux systems, *Antimicrob Agents Chemother*. 43 : 424-427.
- Le Gall, J.R, Lemeshow, S. and Saulnier, F. 1993. A new simplified acute physiology score (SAP II) based on a European/North American multicenter study, *JAMA*. 270 : 2957-2963.

- Levin, A.S., et al. 1999. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, Clin Infect Dis. 28 : 1008-1011.
- Livermore, D.M. 1992. Interplay of impermeability and chromosomal beta-lactamase activity in imipenem-resistant *Pseudomonas aeruginosa*, Antimicrob Agents Chemother. 36 : 2046-2048.
- \_\_\_\_\_. 2001. Of *Pseudomonas*, porins, pumps and carbapenems, J Antimicrob Chemother. 47 : 247-250.
- \_\_\_\_\_. 2002. Multiple mechanisms of antimicrobial resistance in *Pseudomonas aeruginosa* : our worst nightmare?, Clin Infect Dis. 34 : 634-640.
- Livermore, D.M. and Chen, H.Y. 1997. Potentiation of beta-lactams against *Pseudomonas aeruginosa* strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases, J Antimicrob Chemother. 40 : 335-343.
- Morar, P., et al. 1998. Impact of tracheostomy on colonization and infection of Lower airways in children requiring long-term ventilation, Chest. 113 : 77-85.
- Mouneimne, H., et al. 1999. Type II topoisomerase mutations in ciprofloxacin-resistant strains of *Pseudomonas aeruginosa*, Antimicrob Agents Chemother. 43 : 62-66.
- Muder, R.R., et al. 1997. Multiple antibiotic-resistant gram-negative bacilli in a long-term-care facility : a case-control study of patient risk factors and prior antibiotic use, Infect Control Hosp Epidemiol. 18 : 809-813.
- National Antimicrobial Resistance Surveillance Center Thailand. 1998-2000. Antimicrobial susceptibility.
- National Committee for Clinical Laboratory Standards. 2001. Performance Standards for Antimicrobial Susceptibility Testing; Eleventh Informational Supplement, NCCLS document M100-S11. 21 : 46-47.
- Ochs, M.M., et al. 1999. Negative regulation of the *Pseudomonas aeruginosa* outer membrane porin OprD selective for imipenem and basic amino acids, Antimicrob Agents Chemother. 43 : 1085-1090.

- Ohl, C.A. and Pollack, M. 2001. " Infections due to *Pseudomonas* species and related organisms ", In Harrison's Principles of Internal Medicine. 15 th ed, p. 963. Braunwald E, et al., eds. n.p. : McGraw-Hill.
- Okamoto, K., Gotoh, N. and Nishino, T. 2001. *Pseudomonas aeruginosa* reveals high intrinsic resistance to penem antibiotics : penem resistance mechanisms and their interplay, Antimicrob Agents Chemother. 45 : 1964-1971.
- Pingleton, S.K., Fagon, J.Y., Leeper, K.V. 1992. Patient selection for clinical Investigation of ventilator-associated pneumonia : criteria for evaluating Diagnostc techniques, Chest. 102 : 553-558.
- Pollack, M.M., Ruttimann, U.E., Getson, P.R. 1988. Pediatric risk of mortality (PRISM) score, Crit Care Med. 16 : 1110-1116.
- Quinn, J.P. 1998. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens, Clin Infect Dis. 27(suppl1) : s117-24.
- Rasmussen, B.A. 1997. Carbapenem-hydrolyzing  $\beta$ -lactamases, Antimicrob Agents Chemother. 41 : 223-232.
- Senda, K., et al. 1996. Multifocal outbreaks of metallo-beta-lactamase-producing *Pseudomonas aeruginosa* resistant to broad-spectrum beta-lactams, including carbapenems, Antimicrob Agents Chemother. 40 : 349-353.
- Stes, P. and Goosens, H. 1996. Cefepime activity against *Pseudomonas aeruginosa* : Evaluation of E test and two disc diffusion methods, J Antimicrob Chemother. 38 : 707-711.
- Tagigawa, K., et al. 1995. Comparing antimicrobial activity against resistant *Pseudomonas aeruginosa* using an index for the absence of cross-resistance, J Antimicrob Chemother. 35 : 425-427.
- Troillet, N., Samore, M.H. and Carmeli, Y. 1997. Imipenem-resistant *Pseudomonas aeruginosa* : risk factors and antibiotic susceptibility patterns, Clin Infect Dis. 25 : 1094-1098.

Watanabe, N., Hiruma, R. and Katsu, K. 1992. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime and ceftazidime against ceftazidime or imipenem-resistant *Pseudomonas aeruginosa*, J Antimicrob Chemother. 30 : 633-641.